Phase I and pharmacokinetic study of Yondelis(TM) (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

By Twelves C.   Hoekman K.   Bowman A.   Vermorken J.B.   Anthoney A.   Smyth J.   van Kesteren C.   Beijnen J.H.   Uiters J.   Wanders J.   Gomez J.   Guzman C.   Jimeno J.   Hanauske A.   for the New Drug Development Group of the EORTC  

European Journal of Cancer, Vol. 39, Iss. 13, 2003-09 ,pp. : 1842-1851

Elsevier

Access to resources Recommend Favorite

In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors - comparison with the clinical results

By Albella B.   Faircloth G.   Lopez-Lazaro L.   Guzman C.   Jimeno J.   Bueren J.A.  

European Journal of Cancer, Vol. 38, Iss. 10, 2002-07 ,pp. : 1395-1404

Elsevier

Access to resources Recommend Favorite

Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer

By Beumer Jan   Rademaker-Lakhai Jeany   Rosing Hilde   Hillebrand Michel   Bosch Tessa   Lopez-Lazaro Luis   Schellens Jan   Beijnen Jos  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 6, 2007-06 ,pp. : 825-837

Springer Publishing Company

Access to resources Recommend Favorite

Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma

By Schöffski Patrick   Wolter Pascal   Clement Paul   Sciot Raf   De Wever Ivo   Wozniak Agnieszka   Stefan Cristiana   Dumez Herlinde  

Future Oncology, Vol. 3, Iss. 4, 2007-08 ,pp. : 381-392

Future Medicine

Access to resources Recommend Favorite

Editorial comment on ''In vitro toxicity of ET-743 and Aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results'' by Albella and colleagues

By D'Incalci M.  

European Journal of Cancer, Vol. 38, Iss. 10, 2002-07 ,pp. : 1297-1297

Elsevier

Access to resources Recommend Favorite